Why the study?
What are the lipid and nonlipid risk factors predicting angiographic change in men with previous coronary bypass surgery treated with colestipol plus niacin or placebo?
Population
Men with previous coronary bypass surgery
Comparison
Colestipol plus niacin therapy vs Placebo
Design
Cohort, randomized, placebo-controlled
Follow-up
2 years
Key result
In men with previous coronary bypass surgery, non-HDL cholesterol and HDL apolipoprotein C-III were the predominant predictors of global coronary progression in placebo and drug-treated groups.
Authors
Loading...
Non-HDL cholesterol and HDL apolipoprotein C-III may predict post-bypass progression; leaves open causal roles and therapeutic targeting in trials.
RCT
randomized
What are the lipid and nonlipid risk factors predicting angiographic change in men with previous coronary bypass surgery treated with colestipol plus niacin or placebo?
Triglyceride-rich lipoproteins, specifically apolipoprotein C-III and non-HDL cholesterol, play an important role in the progression and regression of human atherosclerosis.
Blankenhorn et al. (1990) conducted an RCT in previous coronary bypass surgery. colestipol plus niacin vs. placebo was evaluated on Global angiographic change, including both native coronary arteries and bypass grafts. In men with previous coronary bypass surgery, non-HDL cholesterol and HDL apolipoprotein C-III were the predominant predictors of global coronary progression in placebo and drug-treated groups.